Abstract: Methods for treating triple negative breast cancer with an androgen receptor inhibitor are provided, as well as methods for screening for the likelihood of the effectiveness of such treatment.

Abstract: The invention provides a treatment of mesothelioma, especially malignant pleural mesothelioma, using an estrogen receptor ? subtype (ER?) agonist, wherein the treatment comprises administering the ER? agonist to the patient, and then after a time, t, of up to 24 hours; administering a platinum-containing anti-cancer drug to the patient. The invention also provides an ER? agonist and a platinum-containing anti-cancer drug for use in the treatment of mesothelioma in a patient, wherein the treatment comprises administering the ER? agonist to the patient, and then after a time, t, of up to 24 hours, administering the platinum-containing anti-cancer drug to the patient; and a kit comprising a platinum-containing anti-cancer drug and an ER? agonist.

Abstract: Nutritional supplement, feed formulation and methods to improve the efficiency of meat production of a bovine animal, using ethyl ferulate as a nutritional supplement; where the administration of ethyl ferulate at bovine animal, is premixed with an excipient food grade, feed formulation, balanced food, concentrated food, and the like. The ethyl ferulate administration is daily during the final stage of fattening bovine animal, wherein the final stage of fattening is 20 to 40 last days.

Abstract: A composition which includes a) ferulic acid ethyl ester and b) one, two or more aryl alkanols. The combination of components a) and b) has an antimicrobial effect on products such as cosmetics.

Abstract: Methods of treating renal cancer, including renal cell carcinoma, using mesalamine are disclosed herein. Mesalamine can be administered as a monotherapy or as part of a comprehensive treatment program, which can also include administration with other anti-cancer drugs, surgical treatments or exposure to ionizing radiation.

Abstract: The present invention provides, inter alia, a composition containing a compound of formula (I): or a pharmaceutically acceptable salt thereof, optionally, in combination with at least one immune checkpoint inhibitor compound. Kits containing the composition, and methods of using the composition for ameliorating or treating the effects of a disease such as a cancer, in a subject, are also provided herein.

Abstract: This invention is directed to the treatment of cancer, particularly castration-resistant prostate cancer and osteolytic bone metastases, with a dual inhibitor of MET and VEGF.

Abstract: The present invention discloses anti-cancer compositions, and associated methods, including an anti-cancer composition comprising: a cellular energy inhibitor having the structure according to formula I wherein X is selected from the group consisting of: a nitro, an imidazole, a halide, sulfonate, a carboxylate, an alkoxide, and amine oxide; and R is selected from the group consisting of: OR?, N(R?)2, C(O)R??, C1-C6 alkyl, C6-C12 aryl, C1-C6 heteroalkyl, a C6-C12 heteroaryl, H, and an alkali metal; where R? represents H, alkali metal, C1-C6 alkyl, C6-C12 aryl or C(O)R??, R? represents H, C1-C6 alkyl, or C6-C12 aryl, and R?? represents H, C1-C20 alkyl or C6-C12 aryl. The anti-cancer composition can additionally comprise at least one sugar, which stabilizes the cellular energy inhibitor by substantially preventing the inhibitor from hydrolyzing. Also, the anti-cancer composition can comprise a hexokinase inhibitor.

Abstract: A ?1-ADR agonist prodrug compound, which is hydrolysable in vivo to release a ?1-ADR agonist compound, and which prodrug compound contains a group which imparts greater lipophilicity and CNS bioavailability to the prodrug compound relative to the ?1-ADR agonist compound.

Abstract: A method for treating a respiratory injury or disease comprising: administering to a patient in need of treatment a pharmaceutical composition comprising a compound of general Formula I: or salt, ester, solvate, hydrate, or prodrug thereof; wherein: x is an integer from 1 to 10; A and B are each, independently, C3-7 cycloalkyl, C3-7 cycloalkyl-C1-6alkyl, C3-7 heterocycloalkyl, C3-7 heterocycloalkyl-C1-6 alkyl, C6-10aryl, C6-10aryl-C1-6alkyl, C3-9 heteroaryl, or C3-9heteroaryl-C1-6alkyl; and n and p are each, independently, integers from 1 to 10; and a pharmaceutically acceptable carrier, excipient, or diluent.

Abstract: The present disclosure is directed to compositions comprising bryostatin-1, and methods comprising administering a composition comprising bryostatin-1, to treat Niemann-Pick Type C in a subject in need thereof.

Abstract: An amide compound represented by formula (I): [wherein A represents a 3- to 7-membered saturated heterocyclic ring which contains, as ring-forming component(s), one or more atoms or groups selected from the group consisting of an oxygen atom and —S(O)t—, t represents 0, etc., R1 and R2 are the same or different and represent a hydrogen atom, etc., n represents 0, etc., the following formula (II): represents a 5-membered aromatic ring, in which Z represents a nitrogen atom or a carbon atom and X1, X2 and X3 are the same or different and represent a nitrogen atom, etc., R3 and R4 are the same or different and represent a hydrogen atom, etc., m represents 0 to 2, Q represents one group selected from group A or a C1 to C8 chain hydrocarbon group optionally having one group selected from group A, Y represents an oxygen atom, etc., u represents 0, etc., and v represents 0, etc.] has excellent arthropod pest controlling effects.

Abstract: The present invention relates to prolonged release pharmaceutical dosage forms comprising hydromorphone or a pharmaceutically acceptable salt thereof and naloxone or a pharmaceutically acceptable salt thereof for use in the treatment of pain.

Abstract: The present disclosure provides methods of treating a subject suffering from or at risk of a BRAF V600 mutation or BRAF fusion mutation related disease or condition, without activating the MAPK pathway or inducing expression of MAPK pathway genes in cells harboring wild-type BRAF.

Abstract: The present invention is directed to methods for treatment of malignancies in companion animals employing dianhydrogalactitol, diacetyldianhydrogalactitol, and dibromodulcitol, as well as analogs and derivatives thereof, in addition to a method to improve the efficacy and/or reduce the side effects of the administration of a therapeutic agent selected from the group consisting of dianhydrogalactitol, a derivative of dianhydrogalactitol, diacetyldianhydrogalactitol, a derivative of diacetyldianhydrogalactitol, dibromodulcitol, and a derivative of dibromodulcitol to a veterinary subject, the method comprising the steps of: (1 (identifying at least one factor or parameter associated with the efficacy and/or occurrence of side effects of the administration of the therapeutic agent to the veterinary subject; and (2) modifying the factor or parameter to improve the efficacy and/or reduce the side effects of the administration of the therapeutic agent to the veterinary subject.

Abstract: The present invention provides compositions and methods for the delivery of antivirals to a cell or subject.

Abstract: The present invention relates to a complex granule formulation comprising a first granular part comprising levocetirizine or its pharmaceutically acceptable salt, cyclodextrin or its derivative, and an alkalinizing agent; and a second granular part comprising montelukast or its pharmaceutically acceptable salt, cyclodextrin or its derivative, and an alkalinizing agent. This formulation can effectively inhibit the production of related compounds of levocetirizine and montelukast by allowing levocetirizine and montelukast to form clathrate complexes with cyclodextrin, and using an alkalinizing agent. This formulation not only shows increased stability and bioavailability, but also improves patient compliance owing to its effective masking of bitter taste.

Abstract: Methods and materials that can be used to regulate macrophage activation are described. Methods can utilize emodin to bi-directionally modulate macrophage activation and return macrophage phenotype to a homeostatic center (e.g., between M1 and M2 phenotypes) in various environmental settings. Methods can target multiple pathologies within a same individual. Methods can be utilized to inhibit macrophage phenotype activation and affect downstream response to phenotype inducing stimulus, thereby altering macrophage memory.

Abstract: The present invention relates to a stable oral liquid pharmaceutical composition of celecoxib or its pharmaceutically acceptable salts thereof. The celecoxib present in the compositions as described herein do not show any precipitation when subjected in Fasted-State Simulated Gastric Fluid (FaSSGF) at pH 2.0, temperature of 37° C.±0.5° C. and under stirring at a speed of 50 rpm at least for 60 minutes. It also relates to the process of preparing and method of using said composition of celecoxib.

Abstract: Biological-based polyurethanes and methods of making the same. The polyurethanes are formed by reacting a biodegradable polyisocyanate (such as lysine diisocyanate) with an optionally hydroxylated biomolecule to form polyurethane. The polymers formed may be combined with ceramic and/or bone particles to form a composite, which may be used as an osteoimplant.